39 research outputs found

    A ring system detected around the Centaur (10199) Chariklo

    Get PDF
    Until now, rings have been detected in the Solar System exclusively around the four giant planets. Here we report the discovery of the rst minor-body ring system around the Centaur object (10199) Chariklo, a body with equivalent radius 124±9 km. A multi-chord stellar occultation revealed the presence of two dense rings around Chariklo, with widths of about 7 km and 3 km, optical depths 0.4 and 0.06, and orbital radii 391 and 405 km, respectively. The present orientation of the ring is consistent with an edge-on geometry in 2008, thus providing a simple explanation for the dimming of Chariklo's system between 1997 and 2008, and for the gradual disappearance of ice and other absorption features in its spectrum over the same period. This implies that the rings are partially composed of water ice. These rings may be the remnants of a debris disk, which were possibly con ned by embedded kilometre-sized satellites

    Clostridioides difficile: innovations in target discovery and potential for therapeutic success

    Get PDF
    Introduction Clostridioides difficile infection (CDI) remains a worldwide clinical problem. Increased incidence of primary infection, occurrence of hypertoxigenic ribotypes, and more frequent occurrence of drug resistant, recurrent, and non-hospital CDI, emphasizes the urgent unmet need of discovering new therapeutic targets. Areas covered We searched PubMed and Web of Science databases for articles identifying novel therapeutic targets or treatments for C. difficile from 2001 to 2021. We present an updated review on current preclinical efforts on designing inhibitory compounds against these drug targets and indicate how these could become the focus of future therapeutic approaches. We also evaluate the increasing exploitability of gut microbial-derived metabolites and host-derived therapeutics targeting VEGF-A, immune targets and pathways, ion transporters, and microRNAs as anti-C. difficile therapeutics, which have yet to reach clinical trials. Our review also highlights the therapeutic potential of re-purposing currently available agents . We conclude by considering translational hurdles and possible strategies to mitigate these problems. Expert opinion Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions is beginning to uncover potential novel therapeutic targets, which can be exploited to plug gaps in the CDI drug discovery pipeline
    corecore